Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: BIOLOGICAL: 9 Peptides from Her-2/neu, CEA, & CTA
Sponsor: Craig L Slingluff, Jr
Collaborators: National Cancer Institute (NCI)